nodes	percent_of_prediction	percent_of_DWPC	metapath
Azelastine—ABCB1—melanoma	0.18	1	CbGaD
Azelastine—CYP1A1—Dacarbazine—melanoma	0.102	0.173	CbGbCtD
Azelastine—CYP2E1—Dacarbazine—melanoma	0.0785	0.134	CbGbCtD
Azelastine—CYP1A2—Carmustine—melanoma	0.0749	0.128	CbGbCtD
Azelastine—CYP1A2—Vemurafenib—melanoma	0.0592	0.101	CbGbCtD
Azelastine—CYP3A4—Temozolomide—melanoma	0.0566	0.0966	CbGbCtD
Azelastine—CYP2D6—Vemurafenib—melanoma	0.0488	0.0832	CbGbCtD
Azelastine—CYP1A2—Dacarbazine—melanoma	0.0454	0.0774	CbGbCtD
Azelastine—ABCB1—Dactinomycin—melanoma	0.0344	0.0587	CbGbCtD
Azelastine—CYP3A4—Vemurafenib—melanoma	0.031	0.0529	CbGbCtD
Azelastine—CYP3A5—Docetaxel—melanoma	0.0273	0.0466	CbGbCtD
Azelastine—ABCB1—Docetaxel—melanoma	0.0178	0.0303	CbGbCtD
Azelastine—CYP3A4—Docetaxel—melanoma	0.0106	0.0182	CbGbCtD
Azelastine—Tearing eyes—Docetaxel—melanoma	0.00451	0.036	CcSEcCtD
Azelastine—Ulcerative stomatitis—Dactinomycin—melanoma	0.00267	0.0213	CcSEcCtD
Azelastine—Mucosal inflammation—Bleomycin—melanoma	0.00238	0.019	CcSEcCtD
Azelastine—Parosmia—Temozolomide—melanoma	0.00172	0.0137	CcSEcCtD
Azelastine—Dysaesthesia—Docetaxel—melanoma	0.00171	0.0136	CcSEcCtD
Azelastine—Atrial fibrillation—Vemurafenib—melanoma	0.00167	0.0133	CcSEcCtD
Azelastine—Arthritis—Vemurafenib—melanoma	0.00163	0.013	CcSEcCtD
Azelastine—Influenza-like symptoms—Temozolomide—melanoma	0.00156	0.0124	CcSEcCtD
Azelastine—Ulcer—Bleomycin—melanoma	0.0014	0.0111	CcSEcCtD
Azelastine—Mucosal inflammation—Docetaxel—melanoma	0.00134	0.0107	CcSEcCtD
Azelastine—Ulcer—Dactinomycin—melanoma	0.0013	0.0104	CcSEcCtD
Azelastine—Breast pain—Temozolomide—melanoma	0.00128	0.0102	CcSEcCtD
Azelastine—Amenorrhoea—Temozolomide—melanoma	0.00127	0.0101	CcSEcCtD
Azelastine—Thinking abnormal—Carmustine—melanoma	0.00126	0.01	CcSEcCtD
Azelastine—Viral infection—Temozolomide—melanoma	0.00123	0.00983	CcSEcCtD
Azelastine—Herpes simplex—Temozolomide—melanoma	0.00121	0.00963	CcSEcCtD
Azelastine—Parosmia—Docetaxel—melanoma	0.00114	0.0091	CcSEcCtD
Azelastine—Mouth ulceration—Dactinomycin—melanoma	0.00111	0.00887	CcSEcCtD
Azelastine—Pharyngolaryngeal pain—Docetaxel—melanoma	0.0011	0.00874	CcSEcCtD
Azelastine—Laryngeal pain—Docetaxel—melanoma	0.00109	0.00866	CcSEcCtD
Azelastine—Influenza like illness—Temozolomide—melanoma	0.00108	0.00862	CcSEcCtD
Azelastine—Eye disorder—Vemurafenib—melanoma	0.00102	0.00815	CcSEcCtD
Azelastine—Abnormal vision—Carmustine—melanoma	0.001	0.00801	CcSEcCtD
Azelastine—Mental disability—Carmustine—melanoma	0.001	0.00797	CcSEcCtD
Azelastine—Arthritis—Bleomycin—melanoma	0.000986	0.00786	CcSEcCtD
Azelastine—Abnormal vision—Temozolomide—melanoma	0.000971	0.00774	CcSEcCtD
Azelastine—Mental disability—Temozolomide—melanoma	0.000966	0.0077	CcSEcCtD
Azelastine—Dysgeusia—Vemurafenib—melanoma	0.000933	0.00743	CcSEcCtD
Azelastine—Eye pain—Carmustine—melanoma	0.000927	0.00739	CcSEcCtD
Azelastine—Back pain—Vemurafenib—melanoma	0.000921	0.00734	CcSEcCtD
Azelastine—Ageusia—Docetaxel—melanoma	0.000914	0.00729	CcSEcCtD
Azelastine—Gastroenteritis—Temozolomide—melanoma	0.000912	0.00727	CcSEcCtD
Azelastine—Eye pain—Temozolomide—melanoma	0.000895	0.00714	CcSEcCtD
Azelastine—Amenorrhoea—Docetaxel—melanoma	0.000843	0.00672	CcSEcCtD
Azelastine—Cough—Vemurafenib—melanoma	0.000831	0.00663	CcSEcCtD
Azelastine—Bronchospasm—Bleomycin—melanoma	0.000815	0.00649	CcSEcCtD
Azelastine—Myalgia—Vemurafenib—melanoma	0.000811	0.00646	CcSEcCtD
Azelastine—Face oedema—Carmustine—melanoma	0.000808	0.00644	CcSEcCtD
Azelastine—Lacrimation increased—Docetaxel—melanoma	0.000804	0.00641	CcSEcCtD
Azelastine—Face oedema—Temozolomide—melanoma	0.00078	0.00622	CcSEcCtD
Azelastine—Anaphylactic shock—Vemurafenib—melanoma	0.000777	0.0062	CcSEcCtD
Azelastine—Infection—Vemurafenib—melanoma	0.000772	0.00616	CcSEcCtD
Azelastine—Influenza like illness—Docetaxel—melanoma	0.000719	0.00573	CcSEcCtD
Azelastine—Alanine aminotransferase increased—Temozolomide—melanoma	0.000713	0.00568	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Vemurafenib—melanoma	0.000708	0.00565	CcSEcCtD
Azelastine—Haematuria—Bleomycin—melanoma	0.000704	0.00561	CcSEcCtD
Azelastine—Bronchitis—Temozolomide—melanoma	0.000672	0.00536	CcSEcCtD
Azelastine—Fatigue—Vemurafenib—melanoma	0.00067	0.00534	CcSEcCtD
Azelastine—Constipation—Vemurafenib—melanoma	0.000665	0.0053	CcSEcCtD
Azelastine—Hypoaesthesia—Bleomycin—melanoma	0.00066	0.00526	CcSEcCtD
Azelastine—Upper respiratory tract infection—Temozolomide—melanoma	0.000649	0.00518	CcSEcCtD
Azelastine—Pollakiuria—Temozolomide—melanoma	0.000645	0.00514	CcSEcCtD
Azelastine—Weight increased—Temozolomide—melanoma	0.000636	0.00507	CcSEcCtD
Azelastine—Flushing—Bleomycin—melanoma	0.000615	0.0049	CcSEcCtD
Azelastine—Body temperature increased—Vemurafenib—melanoma	0.000615	0.0049	CcSEcCtD
Azelastine—Pharyngitis—Dactinomycin—melanoma	0.000614	0.00489	CcSEcCtD
Azelastine—Sinusitis—Temozolomide—melanoma	0.000584	0.00466	CcSEcCtD
Azelastine—Hypoaesthesia—Carmustine—melanoma	0.000576	0.00459	CcSEcCtD
Azelastine—Flushing—Dactinomycin—melanoma	0.000574	0.00457	CcSEcCtD
Azelastine—Hypersensitivity—Vemurafenib—melanoma	0.000573	0.00457	CcSEcCtD
Azelastine—Atrial fibrillation—Docetaxel—melanoma	0.000567	0.00452	CcSEcCtD
Azelastine—Asthenia—Vemurafenib—melanoma	0.000558	0.00445	CcSEcCtD
Azelastine—Visual impairment—Carmustine—melanoma	0.000558	0.00444	CcSEcCtD
Azelastine—Hypoaesthesia—Temozolomide—melanoma	0.000556	0.00444	CcSEcCtD
Azelastine—Pharyngitis—Temozolomide—melanoma	0.000555	0.00442	CcSEcCtD
Azelastine—Pruritus—Vemurafenib—melanoma	0.00055	0.00438	CcSEcCtD
Azelastine—Eye disorder—Carmustine—melanoma	0.000541	0.00431	CcSEcCtD
Azelastine—Visual impairment—Temozolomide—melanoma	0.000539	0.0043	CcSEcCtD
Azelastine—Flushing—Carmustine—melanoma	0.000537	0.00428	CcSEcCtD
Azelastine—Ill-defined disorder—Bleomycin—melanoma	0.000535	0.00427	CcSEcCtD
Azelastine—Diarrhoea—Vemurafenib—melanoma	0.000532	0.00424	CcSEcCtD
Azelastine—Eye disorder—Temozolomide—melanoma	0.000523	0.00417	CcSEcCtD
Azelastine—Malaise—Bleomycin—melanoma	0.00052	0.00415	CcSEcCtD
Azelastine—Flushing—Temozolomide—melanoma	0.000519	0.00414	CcSEcCtD
Azelastine—Dizziness—Vemurafenib—melanoma	0.000514	0.0041	CcSEcCtD
Azelastine—Cough—Bleomycin—melanoma	0.000504	0.00401	CcSEcCtD
Azelastine—Ill-defined disorder—Dactinomycin—melanoma	0.000499	0.00398	CcSEcCtD
Azelastine—Vomiting—Vemurafenib—melanoma	0.000494	0.00394	CcSEcCtD
Azelastine—Chest pain—Bleomycin—melanoma	0.000491	0.00392	CcSEcCtD
Azelastine—Myalgia—Bleomycin—melanoma	0.000491	0.00392	CcSEcCtD
Azelastine—Rash—Vemurafenib—melanoma	0.00049	0.00391	CcSEcCtD
Azelastine—Dermatitis—Vemurafenib—melanoma	0.00049	0.0039	CcSEcCtD
Azelastine—Back pain—Carmustine—melanoma	0.000487	0.00388	CcSEcCtD
Azelastine—Headache—Vemurafenib—melanoma	0.000487	0.00388	CcSEcCtD
Azelastine—Discomfort—Bleomycin—melanoma	0.000485	0.00387	CcSEcCtD
Azelastine—Malaise—Dactinomycin—melanoma	0.000485	0.00387	CcSEcCtD
Azelastine—Nasopharyngitis—Docetaxel—melanoma	0.000481	0.00383	CcSEcCtD
Azelastine—Dysgeusia—Temozolomide—melanoma	0.000477	0.0038	CcSEcCtD
Azelastine—Confusional state—Bleomycin—melanoma	0.000475	0.00379	CcSEcCtD
Azelastine—Vision blurred—Carmustine—melanoma	0.000475	0.00378	CcSEcCtD
Azelastine—Alanine aminotransferase increased—Docetaxel—melanoma	0.000474	0.00378	CcSEcCtD
Azelastine—Anaphylactic shock—Bleomycin—melanoma	0.000471	0.00375	CcSEcCtD
Azelastine—Back pain—Temozolomide—melanoma	0.000471	0.00375	CcSEcCtD
Azelastine—Infection—Bleomycin—melanoma	0.000468	0.00373	CcSEcCtD
Azelastine—Agitation—Carmustine—melanoma	0.000463	0.00369	CcSEcCtD
Azelastine—Nausea—Vemurafenib—melanoma	0.000462	0.00368	CcSEcCtD
Azelastine—Vision blurred—Temozolomide—melanoma	0.000459	0.00366	CcSEcCtD
Azelastine—Myalgia—Dactinomycin—melanoma	0.000458	0.00365	CcSEcCtD
Azelastine—Bronchospasm—Docetaxel—melanoma	0.000457	0.00364	CcSEcCtD
Azelastine—Discomfort—Dactinomycin—melanoma	0.000453	0.00361	CcSEcCtD
Azelastine—Ill-defined disorder—Temozolomide—melanoma	0.000452	0.0036	CcSEcCtD
Azelastine—Agitation—Temozolomide—melanoma	0.000447	0.00357	CcSEcCtD
Azelastine—Malaise—Temozolomide—melanoma	0.000439	0.0035	CcSEcCtD
Azelastine—Vertigo—Temozolomide—melanoma	0.000437	0.00349	CcSEcCtD
Azelastine—Infection—Dactinomycin—melanoma	0.000436	0.00348	CcSEcCtD
Azelastine—Hypertension—Carmustine—melanoma	0.000435	0.00347	CcSEcCtD
Azelastine—Palpitations—Temozolomide—melanoma	0.00043	0.00343	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Bleomycin—melanoma	0.000429	0.00342	CcSEcCtD
Azelastine—Chest pain—Carmustine—melanoma	0.000429	0.00342	CcSEcCtD
Azelastine—Myalgia—Carmustine—melanoma	0.000429	0.00342	CcSEcCtD
Azelastine—Anxiety—Carmustine—melanoma	0.000427	0.00341	CcSEcCtD
Azelastine—Cough—Temozolomide—melanoma	0.000425	0.00339	CcSEcCtD
Azelastine—Paraesthesia—Bleomycin—melanoma	0.000423	0.00337	CcSEcCtD
Azelastine—Weight increased—Docetaxel—melanoma	0.000423	0.00337	CcSEcCtD
Azelastine—Hypertension—Temozolomide—melanoma	0.00042	0.00335	CcSEcCtD
Azelastine—Dyspnoea—Bleomycin—melanoma	0.00042	0.00335	CcSEcCtD
Azelastine—Confusional state—Carmustine—melanoma	0.000415	0.0033	CcSEcCtD
Azelastine—Myalgia—Temozolomide—melanoma	0.000414	0.0033	CcSEcCtD
Azelastine—Anxiety—Temozolomide—melanoma	0.000413	0.00329	CcSEcCtD
Azelastine—Discomfort—Temozolomide—melanoma	0.000409	0.00326	CcSEcCtD
Azelastine—Infection—Carmustine—melanoma	0.000408	0.00326	CcSEcCtD
Azelastine—Dry mouth—Temozolomide—melanoma	0.000405	0.00323	CcSEcCtD
Azelastine—Pain—Bleomycin—melanoma	0.000403	0.00321	CcSEcCtD
Azelastine—Conjunctivitis—Docetaxel—melanoma	0.000403	0.00321	CcSEcCtD
Azelastine—Tachycardia—Carmustine—melanoma	0.000401	0.0032	CcSEcCtD
Azelastine—Confusional state—Temozolomide—melanoma	0.000401	0.00319	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Dactinomycin—melanoma	0.0004	0.00319	CcSEcCtD
Azelastine—Anaphylactic shock—Temozolomide—melanoma	0.000397	0.00317	CcSEcCtD
Azelastine—Infection—Temozolomide—melanoma	0.000395	0.00315	CcSEcCtD
Azelastine—Epistaxis—Docetaxel—melanoma	0.000391	0.00311	CcSEcCtD
Azelastine—Feeling abnormal—Bleomycin—melanoma	0.000388	0.00309	CcSEcCtD
Azelastine—Fatigue—Dactinomycin—melanoma	0.000379	0.00302	CcSEcCtD
Azelastine—Pain—Dactinomycin—melanoma	0.000376	0.00299	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Carmustine—melanoma	0.000375	0.00299	CcSEcCtD
Azelastine—Rhinitis—Docetaxel—melanoma	0.000373	0.00297	CcSEcCtD
Azelastine—Body temperature increased—Bleomycin—melanoma	0.000372	0.00297	CcSEcCtD
Azelastine—Hypoaesthesia—Docetaxel—melanoma	0.00037	0.00295	CcSEcCtD
Azelastine—Paraesthesia—Carmustine—melanoma	0.000369	0.00294	CcSEcCtD
Azelastine—Pharyngitis—Docetaxel—melanoma	0.000369	0.00294	CcSEcCtD
Azelastine—Dyspnoea—Carmustine—melanoma	0.000367	0.00292	CcSEcCtD
Azelastine—Somnolence—Carmustine—melanoma	0.000365	0.00291	CcSEcCtD
Azelastine—Feeling abnormal—Dactinomycin—melanoma	0.000362	0.00289	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Temozolomide—melanoma	0.000362	0.00289	CcSEcCtD
Azelastine—Gastrointestinal pain—Dactinomycin—melanoma	0.000359	0.00286	CcSEcCtD
Azelastine—Visual impairment—Docetaxel—melanoma	0.000358	0.00286	CcSEcCtD
Azelastine—Paraesthesia—Temozolomide—melanoma	0.000357	0.00284	CcSEcCtD
Azelastine—Dyspnoea—Temozolomide—melanoma	0.000354	0.00282	CcSEcCtD
Azelastine—Somnolence—Temozolomide—melanoma	0.000353	0.00282	CcSEcCtD
Azelastine—Pain—Carmustine—melanoma	0.000352	0.0028	CcSEcCtD
Azelastine—Constipation—Carmustine—melanoma	0.000352	0.0028	CcSEcCtD
Azelastine—Eye disorder—Docetaxel—melanoma	0.000348	0.00277	CcSEcCtD
Azelastine—Body temperature increased—Dactinomycin—melanoma	0.000347	0.00277	CcSEcCtD
Azelastine—Abdominal pain—Dactinomycin—melanoma	0.000347	0.00277	CcSEcCtD
Azelastine—Hypersensitivity—Bleomycin—melanoma	0.000347	0.00277	CcSEcCtD
Azelastine—Flushing—Docetaxel—melanoma	0.000345	0.00275	CcSEcCtD
Azelastine—Fatigue—Temozolomide—melanoma	0.000343	0.00273	CcSEcCtD
Azelastine—Pain—Temozolomide—melanoma	0.00034	0.00271	CcSEcCtD
Azelastine—Constipation—Temozolomide—melanoma	0.00034	0.00271	CcSEcCtD
Azelastine—Feeling abnormal—Carmustine—melanoma	0.000339	0.0027	CcSEcCtD
Azelastine—Asthenia—Bleomycin—melanoma	0.000338	0.00269	CcSEcCtD
Azelastine—Gastrointestinal pain—Carmustine—melanoma	0.000336	0.00268	CcSEcCtD
Azelastine—Pruritus—Bleomycin—melanoma	0.000333	0.00266	CcSEcCtD
Azelastine—Feeling abnormal—Temozolomide—melanoma	0.000327	0.00261	CcSEcCtD
Azelastine—Abdominal pain—Carmustine—melanoma	0.000325	0.00259	CcSEcCtD
Azelastine—Body temperature increased—Carmustine—melanoma	0.000325	0.00259	CcSEcCtD
Azelastine—Gastrointestinal pain—Temozolomide—melanoma	0.000325	0.00259	CcSEcCtD
Azelastine—Hypersensitivity—Dactinomycin—melanoma	0.000324	0.00258	CcSEcCtD
Azelastine—Dysgeusia—Docetaxel—melanoma	0.000317	0.00253	CcSEcCtD
Azelastine—Asthenia—Dactinomycin—melanoma	0.000315	0.00251	CcSEcCtD
Azelastine—Body temperature increased—Temozolomide—melanoma	0.000314	0.0025	CcSEcCtD
Azelastine—Abdominal pain—Temozolomide—melanoma	0.000314	0.0025	CcSEcCtD
Azelastine—Back pain—Docetaxel—melanoma	0.000313	0.0025	CcSEcCtD
Azelastine—Hypersensitivity—Carmustine—melanoma	0.000303	0.00241	CcSEcCtD
Azelastine—Diarrhoea—Dactinomycin—melanoma	0.000301	0.0024	CcSEcCtD
Azelastine—Vomiting—Bleomycin—melanoma	0.000299	0.00239	CcSEcCtD
Azelastine—Rash—Bleomycin—melanoma	0.000297	0.00237	CcSEcCtD
Azelastine—Dermatitis—Bleomycin—melanoma	0.000297	0.00236	CcSEcCtD
Azelastine—Asthenia—Carmustine—melanoma	0.000295	0.00235	CcSEcCtD
Azelastine—Hypersensitivity—Temozolomide—melanoma	0.000293	0.00233	CcSEcCtD
Azelastine—Palpitations—Docetaxel—melanoma	0.000286	0.00228	CcSEcCtD
Azelastine—Asthenia—Temozolomide—melanoma	0.000285	0.00227	CcSEcCtD
Azelastine—Cough—Docetaxel—melanoma	0.000282	0.00225	CcSEcCtD
Azelastine—Diarrhoea—Carmustine—melanoma	0.000281	0.00224	CcSEcCtD
Azelastine—Pruritus—Temozolomide—melanoma	0.000281	0.00224	CcSEcCtD
Azelastine—Nausea—Bleomycin—melanoma	0.00028	0.00223	CcSEcCtD
Azelastine—Hypertension—Docetaxel—melanoma	0.000279	0.00223	CcSEcCtD
Azelastine—Vomiting—Dactinomycin—melanoma	0.000279	0.00223	CcSEcCtD
Azelastine—Rash—Dactinomycin—melanoma	0.000277	0.00221	CcSEcCtD
Azelastine—Chest pain—Docetaxel—melanoma	0.000276	0.0022	CcSEcCtD
Azelastine—Myalgia—Docetaxel—melanoma	0.000276	0.0022	CcSEcCtD
Azelastine—Dizziness—Carmustine—melanoma	0.000272	0.00217	CcSEcCtD
Azelastine—Diarrhoea—Temozolomide—melanoma	0.000272	0.00217	CcSEcCtD
Azelastine—Dry mouth—Docetaxel—melanoma	0.00027	0.00215	CcSEcCtD
Azelastine—Confusional state—Docetaxel—melanoma	0.000266	0.00212	CcSEcCtD
Azelastine—Anaphylactic shock—Docetaxel—melanoma	0.000264	0.00211	CcSEcCtD
Azelastine—Dizziness—Temozolomide—melanoma	0.000263	0.00209	CcSEcCtD
Azelastine—Infection—Docetaxel—melanoma	0.000262	0.00209	CcSEcCtD
Azelastine—Vomiting—Carmustine—melanoma	0.000261	0.00208	CcSEcCtD
Azelastine—Nausea—Dactinomycin—melanoma	0.000261	0.00208	CcSEcCtD
Azelastine—Rash—Carmustine—melanoma	0.000259	0.00207	CcSEcCtD
Azelastine—Dermatitis—Carmustine—melanoma	0.000259	0.00206	CcSEcCtD
Azelastine—Tachycardia—Docetaxel—melanoma	0.000258	0.00206	CcSEcCtD
Azelastine—Headache—Carmustine—melanoma	0.000258	0.00205	CcSEcCtD
Azelastine—Vomiting—Temozolomide—melanoma	0.000253	0.00201	CcSEcCtD
Azelastine—Rash—Temozolomide—melanoma	0.00025	0.002	CcSEcCtD
Azelastine—Dermatitis—Temozolomide—melanoma	0.00025	0.00199	CcSEcCtD
Azelastine—Headache—Temozolomide—melanoma	0.000249	0.00198	CcSEcCtD
Azelastine—Nausea—Carmustine—melanoma	0.000244	0.00195	CcSEcCtD
Azelastine—Musculoskeletal discomfort—Docetaxel—melanoma	0.000241	0.00192	CcSEcCtD
Azelastine—Paraesthesia—Docetaxel—melanoma	0.000237	0.00189	CcSEcCtD
Azelastine—Nausea—Temozolomide—melanoma	0.000236	0.00188	CcSEcCtD
Azelastine—Dyspnoea—Docetaxel—melanoma	0.000236	0.00188	CcSEcCtD
Azelastine—Somnolence—Docetaxel—melanoma	0.000235	0.00187	CcSEcCtD
Azelastine—Fatigue—Docetaxel—melanoma	0.000228	0.00182	CcSEcCtD
Azelastine—Pain—Docetaxel—melanoma	0.000226	0.0018	CcSEcCtD
Azelastine—Constipation—Docetaxel—melanoma	0.000226	0.0018	CcSEcCtD
Azelastine—Feeling abnormal—Docetaxel—melanoma	0.000218	0.00174	CcSEcCtD
Azelastine—Gastrointestinal pain—Docetaxel—melanoma	0.000216	0.00172	CcSEcCtD
Azelastine—Abdominal pain—Docetaxel—melanoma	0.000209	0.00166	CcSEcCtD
Azelastine—Body temperature increased—Docetaxel—melanoma	0.000209	0.00166	CcSEcCtD
Azelastine—Hypersensitivity—Docetaxel—melanoma	0.000195	0.00155	CcSEcCtD
Azelastine—Asthenia—Docetaxel—melanoma	0.00019	0.00151	CcSEcCtD
Azelastine—Pruritus—Docetaxel—melanoma	0.000187	0.00149	CcSEcCtD
Azelastine—Diarrhoea—Docetaxel—melanoma	0.000181	0.00144	CcSEcCtD
Azelastine—Dizziness—Docetaxel—melanoma	0.000175	0.00139	CcSEcCtD
Azelastine—Vomiting—Docetaxel—melanoma	0.000168	0.00134	CcSEcCtD
Azelastine—Rash—Docetaxel—melanoma	0.000167	0.00133	CcSEcCtD
Azelastine—Dermatitis—Docetaxel—melanoma	0.000166	0.00133	CcSEcCtD
Azelastine—Headache—Docetaxel—melanoma	0.000166	0.00132	CcSEcCtD
Azelastine—Nausea—Docetaxel—melanoma	0.000157	0.00125	CcSEcCtD
Azelastine—HRH3—Signaling Pathways—AKT1—melanoma	7.59e-06	7.01e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—FN1—melanoma	7.59e-06	7.01e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—melanoma	7.55e-06	6.97e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—GNA11—melanoma	7.48e-06	6.91e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—HIF1A—melanoma	7.46e-06	6.89e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—NOTCH1—melanoma	7.43e-06	6.86e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PIK3CD—melanoma	7.32e-06	6.76e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—FASN—melanoma	7.32e-06	6.76e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CD80—melanoma	7.27e-06	6.72e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PRKCA—melanoma	7.26e-06	6.71e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PIK3CG—melanoma	7.26e-06	6.71e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—APC—melanoma	7.26e-06	6.71e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—KIT—melanoma	7.26e-06	6.71e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—NRAS—melanoma	7.26e-06	6.71e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—VCAN—melanoma	7.24e-06	6.69e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—ALB—melanoma	7.23e-06	6.68e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—ERCC2—melanoma	7.2e-06	6.65e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—SLC5A5—melanoma	7.2e-06	6.65e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—EGF—melanoma	7.18e-06	6.63e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—KDR—melanoma	7.14e-06	6.59e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—ABCB1—melanoma	7.04e-06	6.51e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—MAPK3—melanoma	6.95e-06	6.42e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—GNAQ—melanoma	6.95e-06	6.42e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CD44—melanoma	6.95e-06	6.42e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—melanoma	6.88e-06	6.36e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—FN1—melanoma	6.87e-06	6.34e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—BRAF—melanoma	6.83e-06	6.3e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	6.81e-06	6.29e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	6.75e-06	6.23e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—NOTCH1—melanoma	6.72e-06	6.21e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CG—melanoma	6.72e-06	6.21e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—CYP1B1—melanoma	6.67e-06	6.16e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—IGF1—melanoma	6.65e-06	6.14e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—MAPK1—melanoma	6.62e-06	6.11e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—EGFR—melanoma	6.62e-06	6.11e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CD80—melanoma	6.59e-06	6.08e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CG—melanoma	6.58e-06	6.08e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—APC—melanoma	6.57e-06	6.07e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CG—melanoma	6.57e-06	6.07e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—KIT—melanoma	6.57e-06	6.07e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—NRAS—melanoma	6.57e-06	6.07e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CG—melanoma	6.57e-06	6.07e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	6.51e-06	6.01e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—EGF—melanoma	6.5e-06	6e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PPARG—melanoma	6.49e-06	5.99e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PRKCA—melanoma	6.48e-06	5.99e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—ABCB1—melanoma	6.48e-06	5.98e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—ERCC2—melanoma	6.43e-06	5.94e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MAP2K1—melanoma	6.43e-06	5.94e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—ABCB1—melanoma	6.42e-06	5.93e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PIK3CD—melanoma	6.38e-06	5.9e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PIK3CB—melanoma	6.38e-06	5.89e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PPARG—melanoma	6.35e-06	5.87e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PPARG—melanoma	6.34e-06	5.86e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PRKCA—melanoma	6.33e-06	5.84e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PTGS2—melanoma	6.32e-06	5.84e-05	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—PIK3CA—melanoma	6.32e-06	5.84e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—MAPK3—melanoma	6.3e-06	5.81e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—ERCC2—melanoma	6.28e-06	5.8e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—KRAS—melanoma	6.25e-06	5.77e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CG—melanoma	6.21e-06	5.73e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—BRAF—melanoma	6.18e-06	5.71e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—FGF2—melanoma	6.11e-06	5.65e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CYP17A1—melanoma	6.11e-06	5.64e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—IGF1—melanoma	6.02e-06	5.56e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—MAPK1—melanoma	5.99e-06	5.53e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PPARG—melanoma	5.99e-06	5.53e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—EGFR—melanoma	5.99e-06	5.53e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	5.97e-06	5.51e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PRKCA—melanoma	5.96e-06	5.51e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—ERCC2—melanoma	5.91e-06	5.46e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PRKCA—melanoma	5.91e-06	5.46e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CD—melanoma	5.91e-06	5.46e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	5.88e-06	5.43e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—ERCC2—melanoma	5.86e-06	5.42e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—ALB—melanoma	5.83e-06	5.39e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MAP2K1—melanoma	5.82e-06	5.37e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CD—melanoma	5.79e-06	5.34e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CD—melanoma	5.78e-06	5.34e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CD—melanoma	5.77e-06	5.33e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GNA11—melanoma	5.77e-06	5.33e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—PIK3CA—melanoma	5.74e-06	5.3e-05	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—PIK3CA—melanoma	5.72e-06	5.29e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MDM2—melanoma	5.72e-06	5.28e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—ALB—melanoma	5.71e-06	5.28e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—ALB—melanoma	5.7e-06	5.26e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CG—melanoma	5.69e-06	5.25e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—KRAS—melanoma	5.66e-06	5.23e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—FASN—melanoma	5.65e-06	5.22e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—ERBB2—melanoma	5.64e-06	5.21e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PIK3CB—melanoma	5.56e-06	5.14e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—SLC5A5—melanoma	5.56e-06	5.13e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—FGF2—melanoma	5.53e-06	5.11e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PTEN—melanoma	5.51e-06	5.09e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PPARG—melanoma	5.49e-06	5.07e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—ABCB1—melanoma	5.49e-06	5.07e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CD—melanoma	5.46e-06	5.04e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—ALB—melanoma	5.39e-06	4.97e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—GNAQ—melanoma	5.37e-06	4.96e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CD44—melanoma	5.37e-06	4.96e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CXCL8—melanoma	5.35e-06	4.94e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	5.33e-06	4.92e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—HRAS—melanoma	5.31e-06	4.91e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CDKN1B—melanoma	5.22e-06	4.82e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—PIK3CA—melanoma	5.2e-06	4.8e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MDM2—melanoma	5.18e-06	4.78e-05	CbGpPWpGaD
Azelastine—ADRA1B—GPCR downstream signaling—AKT1—melanoma	5.17e-06	4.77e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CB—melanoma	5.15e-06	4.76e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—CYP1B1—melanoma	5.14e-06	4.75e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CASP3—melanoma	5.12e-06	4.73e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—IL2—melanoma	5.11e-06	4.72e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—ERBB2—melanoma	5.1e-06	4.71e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PTGS2—melanoma	5.1e-06	4.71e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—IL6—melanoma	5.08e-06	4.7e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CG—melanoma	5.08e-06	4.69e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PRKCA—melanoma	5.05e-06	4.67e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CB—melanoma	5.04e-06	4.66e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CB—melanoma	5.04e-06	4.65e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CB—melanoma	5.03e-06	4.65e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—ERCC2—melanoma	5.01e-06	4.63e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CD—melanoma	5e-06	4.62e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PTGS2—melanoma	5e-06	4.62e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PTGS2—melanoma	4.99e-06	4.61e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CCND1—melanoma	4.98e-06	4.6e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CG—melanoma	4.96e-06	4.58e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—ALB—melanoma	4.94e-06	4.56e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CTNNB1—melanoma	4.93e-06	4.56e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PPARG—melanoma	4.9e-06	4.53e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	4.86e-06	4.49e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CXCL8—melanoma	4.84e-06	4.47e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MMP9—melanoma	4.84e-06	4.47e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—CDKN1A—melanoma	4.82e-06	4.45e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—HRAS—melanoma	4.81e-06	4.44e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PTEN—melanoma	4.81e-06	4.44e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—NFKB1—melanoma	4.79e-06	4.42e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PPARG—melanoma	4.78e-06	4.42e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CB—melanoma	4.75e-06	4.39e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CDKN1B—melanoma	4.73e-06	4.37e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PTGS2—melanoma	4.71e-06	4.35e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling by GPCR—AKT1—melanoma	4.69e-06	4.33e-05	CbGpPWpGaD
Azelastine—HRH1—GPCR downstream signaling—AKT1—melanoma	4.68e-06	4.32e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CG—melanoma	4.67e-06	4.31e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CASP3—melanoma	4.63e-06	4.28e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CG—melanoma	4.63e-06	4.28e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—IL2—melanoma	4.63e-06	4.27e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—IL6—melanoma	4.6e-06	4.25e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CCND1—melanoma	4.51e-06	4.17e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PPARG—melanoma	4.51e-06	4.16e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PPARG—melanoma	4.47e-06	4.13e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CTNNB1—melanoma	4.47e-06	4.12e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CD—melanoma	4.46e-06	4.12e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PTEN—melanoma	4.45e-06	4.11e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—ALB—melanoma	4.41e-06	4.07e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MMP9—melanoma	4.38e-06	4.04e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—CDKN1A—melanoma	4.36e-06	4.03e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CB—melanoma	4.36e-06	4.03e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PTEN—melanoma	4.36e-06	4.03e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CD—melanoma	4.36e-06	4.02e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PTEN—melanoma	4.35e-06	4.02e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PTEN—melanoma	4.35e-06	4.02e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—VEGFA—melanoma	4.34e-06	4.01e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—NFKB1—melanoma	4.33e-06	4e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PTGS2—melanoma	4.32e-06	3.99e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—ALB—melanoma	4.3e-06	3.97e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—STAT3—melanoma	4.3e-06	3.97e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—NRAS—melanoma	4.29e-06	3.96e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling by GPCR—AKT1—melanoma	4.25e-06	3.92e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—ABCB1—melanoma	4.24e-06	3.91e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	4.15e-06	3.83e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PTEN—melanoma	4.11e-06	3.8e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MAPK3—melanoma	4.11e-06	3.79e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CD—melanoma	4.11e-06	3.79e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CD—melanoma	4.07e-06	3.76e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—ALB—melanoma	4.05e-06	3.74e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—ALB—melanoma	4.02e-06	3.71e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MYC—melanoma	4e-06	3.69e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CG—melanoma	3.96e-06	3.65e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—VEGFA—melanoma	3.93e-06	3.63e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—MAPK1—melanoma	3.91e-06	3.61e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—EGFR—melanoma	3.91e-06	3.61e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PRKCA—melanoma	3.9e-06	3.6e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—STAT3—melanoma	3.89e-06	3.6e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CB—melanoma	3.89e-06	3.59e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—PIK3CA—melanoma	3.89e-06	3.59e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—NRAS—melanoma	3.88e-06	3.59e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—ERCC2—melanoma	3.87e-06	3.57e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PTGS2—melanoma	3.86e-06	3.56e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PPARG—melanoma	3.82e-06	3.53e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CB—melanoma	3.8e-06	3.51e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PTEN—melanoma	3.77e-06	3.48e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PTGS2—melanoma	3.76e-06	3.48e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MAPK3—melanoma	3.72e-06	3.43e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—KRAS—melanoma	3.69e-06	3.41e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MYC—melanoma	3.62e-06	3.34e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CB—melanoma	3.58e-06	3.31e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CB—melanoma	3.55e-06	3.28e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PTGS2—melanoma	3.55e-06	3.28e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—MAPK1—melanoma	3.54e-06	3.27e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—EGFR—melanoma	3.54e-06	3.27e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PTGS2—melanoma	3.52e-06	3.25e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CD—melanoma	3.48e-06	3.21e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—ALB—melanoma	3.43e-06	3.17e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—PIK3CA—melanoma	3.39e-06	3.13e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PTEN—melanoma	3.36e-06	3.11e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—KRAS—melanoma	3.34e-06	3.09e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PTEN—melanoma	3.28e-06	3.03e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—TP53—melanoma	3.28e-06	3.03e-05	CbGpPWpGaD
Azelastine—CYP2A6—Metabolism—AKT1—melanoma	3.18e-06	2.94e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—PIK3CA—melanoma	3.14e-06	2.9e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—HRAS—melanoma	3.14e-06	2.9e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PTEN—melanoma	3.09e-06	2.86e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—PIK3CA—melanoma	3.07e-06	2.84e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—PIK3CA—melanoma	3.07e-06	2.84e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—PIK3CA—melanoma	3.07e-06	2.83e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PTEN—melanoma	3.07e-06	2.83e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CG—melanoma	3.05e-06	2.82e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CB—melanoma	3.03e-06	2.8e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PTGS2—melanoma	3e-06	2.77e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—IL6—melanoma	3e-06	2.77e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—TP53—melanoma	2.97e-06	2.74e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PPARG—melanoma	2.95e-06	2.72e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—PIK3CA—melanoma	2.9e-06	2.68e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—HRAS—melanoma	2.84e-06	2.62e-05	CbGpPWpGaD
Azelastine—ADRA1B—Signaling Pathways—AKT1—melanoma	2.77e-06	2.56e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—IL6—melanoma	2.72e-06	2.51e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CD—melanoma	2.68e-06	2.48e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—PIK3CA—melanoma	2.66e-06	2.45e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—ALB—melanoma	2.65e-06	2.45e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PTEN—melanoma	2.62e-06	2.42e-05	CbGpPWpGaD
Azelastine—CYP2B6—Metabolism—AKT1—melanoma	2.56e-06	2.37e-05	CbGpPWpGaD
Azelastine—CYP2E1—Metabolism—AKT1—melanoma	2.51e-06	2.32e-05	CbGpPWpGaD
Azelastine—HRH1—Signaling Pathways—AKT1—melanoma	2.51e-06	2.32e-05	CbGpPWpGaD
Azelastine—CYP3A5—Metabolism—AKT1—melanoma	2.51e-06	2.32e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—PIK3CA—melanoma	2.37e-06	2.19e-05	CbGpPWpGaD
Azelastine—CYP1A1—Metabolism—AKT1—melanoma	2.37e-06	2.19e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CB—melanoma	2.34e-06	2.16e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PTGS2—melanoma	2.32e-06	2.14e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—PIK3CA—melanoma	2.32e-06	2.14e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—PIK3CA—melanoma	2.18e-06	2.02e-05	CbGpPWpGaD
Azelastine—CYP2C8—Metabolism—AKT1—melanoma	2.17e-06	2.01e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—PIK3CA—melanoma	2.16e-06	2e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PTEN—melanoma	2.02e-06	1.87e-05	CbGpPWpGaD
Azelastine—CYP2C19—Metabolism—AKT1—melanoma	1.94e-06	1.79e-05	CbGpPWpGaD
Azelastine—ABCB1—Metabolism—AKT1—melanoma	1.89e-06	1.75e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—PIK3CA—melanoma	1.85e-06	1.71e-05	CbGpPWpGaD
Azelastine—CYP2D6—Metabolism—AKT1—melanoma	1.78e-06	1.65e-05	CbGpPWpGaD
Azelastine—CYP2C9—Metabolism—AKT1—melanoma	1.77e-06	1.63e-05	CbGpPWpGaD
Azelastine—CYP1A2—Metabolism—AKT1—melanoma	1.51e-06	1.39e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—PIK3CA—melanoma	1.43e-06	1.32e-05	CbGpPWpGaD
Azelastine—CYP3A4—Metabolism—AKT1—melanoma	1.17e-06	1.08e-05	CbGpPWpGaD
